Halozyme Shares Fall More Than 13% After Leerink Downgrade

Enna Lee

1 min read

Add as a preferred source on Google

Halozyme Shares Fall More Than 13% After Leerink Downgrade

Third-quarter revenue rose 39% to $493 million, while non-GAAP earnings came in 3 cents above estimates.

By Enna Lee

Published Nov 8, 2026, 8:13 AM EST

An unmarked syringe rests beside a small glass vial / TokenPost.ai

Halozyme Therapeutics (HALO) shares fell more than 13% Friday, Nov. 6, after Leerink Partners downgraded the drug-delivery technology developer following a quarter that only marginally exceeded analyst forecasts.

The company reported third-quarter revenue of $493 million, up 39% from a year earlier. Non-GAAP earnings were $2.39 per share, 3 cents above estimates, while revenue exceeded estimates by $1.44 million.

Halozyme also raised its 2026 revenue outlook to $1.86 billion to $1.925 billion.

Enna Lee

Reporter

Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.